Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

医学 重症肌无力 耐受性 不利影响 抗原 嵌合抗原受体 自身抗体 免疫疗法 内科学 胃肠病学 免疫学 抗体 癌症
作者
Volkan Granit,Michael Benatar,Metin Kurtoğlu,Miloš D. Miljković,Nizar Chahin,Gregory Sahagian,Marc H. Feinberg,Adam Slansky,Tuan Vu,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu,James F. Howard,Tahseen Mozaffar,Volkan Granit,Michael Benatar,Tahseen Mozaffar,Nizar Chahin,James F. Howard,Adam D. Slansky
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (7): 578-590 被引量:128
标识
DOI:10.1016/s1474-4422(23)00194-1
摘要

Background Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)—rather than the conventional DNA approach—to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells. Methods MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III–IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II–IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051. Findings We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3–9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were –6 (95% CI –9 to –3) for MG-ADL score, –7 (–11 to –3) for Quantitative Myasthenia Gravis score, –14 (–19 to –9) for Myasthenia Gravis Composite score, and –9 (–15 to –3) for Myasthenia Gravis Quality of Life 15-revised score. Interpretation In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases. Funding Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
完美世界应助甘愿采纳,获得10
1秒前
1秒前
2秒前
2秒前
Denning发布了新的文献求助10
3秒前
3秒前
貔貅完成签到,获得积分10
3秒前
4秒前
Liufgui应助氯化钾芝士采纳,获得10
4秒前
飞天817发布了新的文献求助10
4秒前
活力臻发布了新的文献求助10
5秒前
依然小爽完成签到,获得积分10
5秒前
Flynn完成签到,获得积分10
5秒前
852应助沐晴采纳,获得30
6秒前
ff发布了新的文献求助10
6秒前
赶路人完成签到,获得积分10
7秒前
崔懿龍发布了新的文献求助10
8秒前
8秒前
8秒前
小张发布了新的文献求助10
9秒前
Liufgui应助徐智秀采纳,获得20
9秒前
焦糖发布了新的文献求助20
9秒前
薇薇快跑完成签到,获得积分20
10秒前
Orange应助独特的凝云采纳,获得10
10秒前
10秒前
11秒前
万能图书馆应助轻歌水越采纳,获得10
11秒前
量子星尘发布了新的文献求助10
11秒前
lm发布了新的文献求助10
13秒前
14秒前
yewungs完成签到,获得积分10
14秒前
薇薇快跑发布了新的文献求助10
14秒前
小坤同学发布了新的文献求助10
15秒前
16秒前
16秒前
111完成签到,获得积分20
17秒前
活泼水桃发布了新的文献求助10
17秒前
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Economic Geography and Public Policy 900
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021